Pharmacological and x-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats.

@article{Ostrowski2007PharmacologicalAX,
  title={Pharmacological and x-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats.},
  author={Jacek Ostrowski and Joyce E Kuhns and John A. Lupisella and Mark C Manfredi and Blake C. Beehler and Stanley R. Krystek and Yingzhi Bi and Chongqing Sun and Ramakrishna Seethala and Rajasree Golla and Paul G. Sleph and Aberra Fura and Yongmi An and Kevin F Kish and John S. Sack and Kasim A Mookhtiar and Gary James Grover and Lawrence G. Hamann},
  journal={Endocrinology},
  year={2007},
  volume={148 1},
  pages={4-12}
}
A novel, highly potent, orally active, nonsteroidal tissue selective androgen receptor (AR) modulator (BMS-564929) has been identified, and this compound has been advanced to clinical trials for the treatment of age-related functional decline. BMS-564929 is a subnanomolar AR agonist in vitro, is highly selective for the AR vs. other steroid hormone receptors, and exhibits no significant interactions with SHBG or aromatase. Dose response studies in castrated male rats show that BMS-564929 is… CONTINUE READING